SCHEMBL188821

SCHEMBL188821

NNc1ccncc1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 16/20 0.55
KDM6B O15054 7/20 0.55
KDM4D Q6B0I6 4/20 0.55
KDM4E B2RXH2 2/20 0.55
KDM4A O75164 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
MEN1 O00255 1/20 0.55
ALDH1A1 P00352 1/20 0.55
MAPT P10636 1/20 0.55
THRB P10828 1/20 0.55
KMT2A Q03164 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
SIRT3 Q9NTG7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19611328 1.00 KDM4C (0.55) KDM4CKDM6BKDM4DKDM4EKDM4A
Acetone SCHEMBL2032550 0.94 KDM4C (0.54) KDM4CKDM6BKDM4DKDM4EKDM4A
Acetone SCHEMBL15923153 0.93 KDM4C (0.53) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL1255875 0.88 KDM4C (0.49) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL12830011 0.86 KDM4C (0.68) KDM4CKDM6BKDM4DKDM4EKDM4A
Succinimide SCHEMBL28021262 0.86 KDM4C (0.43) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL662028 0.84 SIRT3 (0.58) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL3823398 0.84 KDM4C (0.76) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL9616247 0.84 KDM4C (0.55) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL4654937 0.82 CA12 (0.49) KDM4CKDM6BKDM4DKDM4EKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250367305-A1 ALBUMIN NANOCOMPOSITE COMPRISING PHYTOCHEMICAL AND COMPOSITION FOR IMPROVING MUSCLE DISEASE CONTAINING SAME SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-12-04 US claimed
US-20250288704-A1 CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF Technische Universität München (DE) 2025-09-18 US claimed
US-20250276071-A1 NANOPLATFORM FOR TARGETING INFLAMMATORY MACROPHAGES, AND COMPOSITION CONTAINING SAME FOR PREVENTING OR TREATING INFLAMMATORY DISEASES CLICHEMBIO, INC (KR) 2025-09-04 US claimed
EP-4585209-A1 NANOPLATFORM FOR TARGETING INFLAMMATORY MACROPHAGES, AND COMPOSITION CONTAINING SAME FOR PREVENTING OR TREATING INFLAMMATORY DISEASES Clichembio, Inc. (KR) 2025-07-16 EP claimed
US-12208146-B2 Reconstituted HDL nanoparticles for delivery of radioactive agents and uses thereof UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) 2025-01-28 US claimed
US-20250019402-A1 PHARMACOKINETICS AND CHOLECYSTOKININ-2 RECEPTOR (CCK2R) TARGETING FOR DIAGNOSIS AND THERAPY MEDIZINISCHE UNIV INNSBRUCK (AT) 2025-01-16 US claimed
US-20240317780-A1 RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF Technische Universität München (DE) 2024-09-26 US claimed
WO-2024177490-A1 ALBUMIN NANOCOMPOSITE COMPRISING PHYTOCHEMICAL AND COMPOSITION FOR IMPROVING MUSCLE DISEASE CONTAINING SAME 서울대학교산학협력단 2024-08-29 WO claimed
US-20240199722-A1 NANOPLATFORM FOR TARGETING MACROPHAGE AND COMPOSITION FOR PREVENTION OR TREATMENT OF METASTATIC CANCER SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2024-06-20 US claimed
WO-2024112181-A1 NANOPLATFORM FOR TARGETING INFLAMMATORY MACROPHAGES, AND COMPOSITION CONTAINING SAME FOR PREVENTING OR TREATING INFLAMMATORY DISEASES (주)클리켐바이오 2024-05-30 WO claimed
WO-2016046793-A2 RADIOPHARMACEUTICAL CONJUGATE THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) 2016-03-31 WO claimed
EP-1934251-B1 INTERLEUKIN-8 LABELLED VIA ONE OR MORE SITE SPECIFICALLY CONJUGATED HYDRAZINONICOTINAMIDE (HYNIC) MOIETIES AND ITS USE IN DIAGNOSIS OF INFECTION AND INFLAMMATION STICHTING KATHOLIEKE UNIV (NL) 2010-06-16 EP claimed
US-20080233084-A1 Interleukin-8 Labelled Via One or More Site Specifically Conjugated Hydrazinonicotinamide (Hynic) Moieties and its Use in Diagnosis of Infection and Inflammation STICHTING KATHOLIEKE UNIVERSITEIT OF NIJMEGEN (NL) 2008-09-25 US claimed
EP-1934251-A2 INTERLEUKIN-8 LABELLED VIA ONE OR MORE SITE SPECIFICALLY CONJUGATED HYDRAZINONICOTINAMIDE (HYNIC) MOIETIES AND ITS USE IN DIAGNOSIS OF INFECTION AND INFLAMMATION Stichting Katholieke Universiteit (NL) 2008-06-25 EP claimed
US-20070258893-A1 Compositions and methods for imaging expression of cell surface receptors SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KP) 2007-11-08 US claimed
WO-2007042946-A2 INTERLEUKIN-8 LABELLED VIA ONE OR MORE SITE SPECIFICALLY CONJUGATED HYDRAZINONICOTINAMIDE (HYNIC) MOIETIES AND ITS USE IN DIAGNOSIS OF INFECTION AND INFLAMMATION STICHTING KATHOLIEKE UNIVERSITEIT (NL) 2007-04-19 WO claimed
EP-0869821-B1 STEREOISOMERS OF FATTY ACID ANALOGS FOR DIAGNOSTIC IMAGING MOLECULAR INSIGHT PHARM INC (US) 2007-01-31 EP claimed
EP-0869820-B1 CARDIOVASCULAR AND THROMBUS IMAGING AGENTS, METHODS AND KITS GEN HOSPITAL CORP (US) 2005-03-09 EP claimed
EP-0975373-B1 RADIONUCLIDE ASSOCIATED WITH NUCLEOTIDE POLYPHOSPHATE AS TUMOR IMAGING AGENTS GEN HOSPITAL CORP (US) 2005-01-26 EP claimed
US-6491893-B1 ADMINISTERING COLONY STIMULATING FACTORS AND RADIONUCLIDE LABELS, THEN DETECTING USING TOMOGRAPHY OR MAGNETIC RESONANCE IMAGING BIOSTREAM, INC. 2002-12-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199722-A1 NANOPLATFORM FOR TARGETING MACROPHAGE AND COMPOSITION FOR PREVENTION OR TREATMENT OF METASTATIC CANCER SIGLEC9, B3GNT2, NEU3 KDM4C 3780/4885KDM6B 4072/4885KDM4D 2941/4885
US-20250276071-A1 NANOPLATFORM FOR TARGETING INFLAMMATORY MACROPHAGES, AND COMPOSITION CONTAINING SAME FOR PREVENTING OR TREATING INFLAMMATORY DISEASES GLS, TNF, ARG2 KDM4C 3733/4885KDM6B 2564/4885KDM4D 4193/4885
US-20250288704-A1 CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF CXCR4, CXCR1, CXCR3 KDM4C 4231/4885KDM6B 4771/4885KDM4D 4083/4885
US-20240317780-A1 RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF SSTR1, SSTR3, SSTR4 KDM4C 4480/4885KDM6B 4276/4885KDM4D 4372/4885
US-20250367305-A1 ALBUMIN NANOCOMPOSITE COMPRISING PHYTOCHEMICAL AND COMPOSITION FOR IMPROVING MUSCLE DISEASE CONTAINING SAME ALB, TNNC1, MYOF KDM4C 3770/4885KDM6B 2814/4885KDM4D 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.